News

COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair

In early January, responding to the escalating global health crisis, BenevolentAI experts deployed our technology to identify approved drugs that could be used to treat COVID-19. Using our AI tools and biomedical knowledge graph, the team uncovered baricitinib, an approved rheumatoid arthritis drug owned by Eli Lilly, as a potential treatment.


This discovery was made by exploring ways to inhibit the cellular processes that the virus uses to infect human cells. The aim was to identify existing medicines that could potentially stop the progression of COVID-19, inhibit the “cytokine storm” and reduce the inflammatory damage associated with this disease. The team hypothesised that baricitinib may also have antiviral properties, based on its predicted ability to inhibit two members of Numb-associated kinase (NAK) family, AAK1 and GAK.

The team believes that by blocking the virus and reducing inflammation in advanced-stage patients can help to save lives, as it is the severe inflammation that causes death meaning lungs fill with fluid and patients can no longer breathe.

In a recent publication in EMBO Molecular Medicine a team of international scientists from BenevolentAI, Eli Lilly, Karolinska and clinicians in Milan validate this artificial intelligence‐assisted prediction. Using liver organoids infected with SARS‐CoV‐2, they confirm dual antiviral and anti‐inflammatory activities. They also show disease improvement in four COVID‐19 patients who were given baricitinib, paving the way for more rigorous placebo‐controlled trials.

In this editorial comment, Michael B. Schultz, Daniel Vera and David Sinclair review these findings and explore the broader, longer-term implications of the AI-powered study on drug discovery: “Here, the marriage of machine learning and rapid clinical trials provides hope for progress, not only in today’s fight against COVID-19, but in the ongoing fight against acute and chronic diseases”.

Access the review in EMBO Molecular Medicine:

PUBLICATION


More Posts

You Might Also Like

News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
Events
New tech brings new hope in our new normal | A Keynote from Joanna Shields at WeAreTechWomen
In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.
Jun 26, 2020
Events
Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.
Our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease
Jun 9, 2020
Video
How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Events
Women in Biotech with Peju Oshisanya
Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedical research and how we can avoid the pitfalls.
Jun 4, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020